The efficiency of biologic therapy in a group of patients with rheumatoid arthritis

Gavrilă BI*, Ciofu C*, Stoica V*, Panaitescu E**

**“Dr. I. Cantacuzino” Clinical Hospital, Bucharest, Department of Internal Medicine and Rheumatology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

**Department of Medical Informatics and Biostatistics, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

Correspondence to: Bogdan Ion Gavrilă, MD
“Dr. I. Cantacuzino” Clinical Hospital,
5-7 Ion Movila Street, 020475, Bucharest, Romania
Mobile phone: +40 724 556 396, E-mail: bogdang135@yahoo.com

Received: September 14th, 2014 – Accepted: December 15th, 2014

Abstract

Objectives. The following study aims to evaluate the monotherapy with biologic agents: Infliximab (IFX), Etanercept (ETA), Adalimumab (ADA) and Rituximab (RTX) in patients diagnosed with rheumatoid arthritis (RA).

Methods. To achieve these objectives, the database of “Dr. I. Cantacuzino” Clinical Hospital, Department of Internal Medicine and Rheumatology, was used.

The study was retrospective and descriptive, covering 168 patients with RA, followed for 12 months, from January 2012 to January 2013.

Admission criteria for the study were the following: patients diagnosed with RA according to ACR 1987/ EULAR 2010 criteria, disease activity score (DAS 28)> 5.1, positive inflammation tests, presence of RA refractory to classic remitting treatment administered at least 6 months prior to the initiation of biological therapy, on patients treated with RTX. They were considered non-responders after 6 months of treatment with anti tumor necrosis factor alpha (anti-TNF) and decided to switch agents with anti CD-20.

Results. Comparing values between any two points in time (baseline - 6 months -12 months) for any type of therapy, there were significant decreases in the values of erythrocyte sedimentation rate (ESR), reactive C protein (CRP) and disease activity score (DAS 28).

There were no significant differences between therapies regarding ESR at 6 months (p = 0.070, ANOVA) and 12 months (p = 0.375, Kruskal-Wallis), significant differences were regarding CRP at 6 and 12 months (p = 0.000, Kruskal-Wallis) and DAS 28 at 6 months (p = 0.000, Kruskal-Wallis) and 12 months (p = 0.018, Kruskal-Wallis).

Conclusion. All 4 therapies have proven efficient, prognostic markers decreasing gradually at 6 and 12 months.

Keywords: rheumatoid arthritis, biologic therapy

Abbreviations: RA = rheumatoid arthritis, IFX = Infliximab, ETA = Etanercept, ADA = Adalimumab, RTX = Rituximab, ESR = erythrocyte sedimentation rate, CRP = reactive C protein, DAS 28 = disease activity score, anti TNF = inhibitor of tumor necrosis factor

Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease with an incomplete elucidated etiology, presenting multiple extra-articular manifestations [1].

The disease may have an acute or insidious onset, and often progresses with major osteochondral lesions from the beginning. It has a prevalence of 1% within the general population and the severity of the disease is caused by various degrees of disability from the first two years.

The major impact on the body and the quality of life induces a higher level of morbidity and mortality, and therefore it is necessary to start an appropriate treatment as early as possible.

In addition to non-pharmacological therapies, therapeutic options in the treatment of AR are classic remitting drugs, biologic therapies, nonsteroidal anti-inflammatory drugs (NSAIDs) and steroids (glucocorticoids).

The basic treatment of RA includes disease-modifying antirheumatic drugs (DMARDs). This includes two major classes: synthetic compounds (sDMARDs) and biological agents (bDMARDs).

In 2013, Smolen JS et al. proposed a new classification, as it follows: the class sDMARDs contained
synthetic conventional agents such as methotrexate, leflunomide, sulfasalazine, which were called csDMARDs, and a new agent sDMARDs - Tofacitinib (Janus Kinase inhibitor), which was included in the category of target agents - tsDMARDs.

The five inhibitors of the tumor necrosis factor (anti-TNF): Adalimumab, Etanercept, Infliximab, Golimumab, Certolizumab, the inhibitory agent to the co-stimulatory molecules (Abatacept), anti-CD20 (Rituximab), the inhibitors of interleukin-1 monoclonal antibodies (Anakinra) and interleukin 6 (Tocilizumab) were treated as original biological molecules - boDMARDs, while biosimilars recently approved by the European Medicines Agency (EMA) are included in the category of bsDMARDs [2,3].

Infliximab is a chimeric monoclonal antibody (murine and human) with a complex mechanism of action. It is administered as an infusion, having a dose of 3-5 to 10 mg/ kg body weight. This agents' infusions induction is performed at weeks 0, 2 and 6, and thereafter the treatment is administered by infusion at every 8 weeks [4].

Etanercept, an antibody that acts in the soluble receptors of TNF, is administered as a subcutaneous injection; phials of 25 mg are administered 2 times/ week and 50 mg phials once a week [5].

Adalimumab, a human anti TNF inhibitor is administered subcutaneously, 40 mg at every 2 weeks. Favorable effects were demonstrated both cutaneous and articular [6].

Rituximab is a chimeric anti-lymphocyte monoclonal antibody B/ CD-20. 1,000 mg/ i.v. are administered at 2 weeks (2 x 500 mg), followed by a further cure to 6 months. This therapy is used in patients who have not responded to anti-TNF therapy or for patients with contraindications to treatment with anti-TNF therapy (e.g. various neoplastic diseases) [7,8].

Objectives

The objective of the study was to evaluate the efficacy of biological agents: Infliximab, Etanercept, Adalimumab and Rituximab in patients diagnosed with severe and active RA.

The main parameters used to assess the efficacy of the treatment were the following: DAS 28 score, ESR and CRP. These markers were determined three times during the study: baseline, at six months and at twelve months.

Methods

To achieve these objectives, the database of “Dr. I. Cantacuzino” Clinical Hospital, Department of Internal Medicine and Rheumatology, was used. The study was retrospective, descriptive and included 168 patients with RA, followed for 12 months, from January 2012 to January 2013.

The inclusion criteria for the study were the following:

- patients who were diagnosed with RA according to ACR 1987/ EULAR 2010 criteria [9,10],
- with DAS 28 > 5.1,
- positive inflammation tests: CRP> 5 mg/ dl, ESR> 15 mm/ h,
- presence of RA refractory to classic remitting treatment administered at least 6 months prior to the initiation of biological therapy (maximum dose possible of two drugs, one should be Methotrexate unless contraindicated/ intolerance),
- written consent for the administration of the biological treatment,
- on patients treated with Rituximab, they were considered non-responders after 6 months of treatment with anti TNF and decided to switch agents with anti CD-20.

All the patients were clinically and laboratory assessed before the use of biological treatment and then at every 6 and 12 months. Each patient was assessed by the treating physician, having the possibility to change the therapy if clinical and laboratory parameters were not improved as recommended by EULAR [11].

Statistical analysis

Variations of DAS 28 score, ESR, CRP were expressed as mean ± SD or median and quartile 25% respectively 75%. When comparing values between different time groups (0, 6, 12 months) the Student test was used in pairs with Bonferroni correction.

For comparison, ANOVA or Kruskall Wallis tests were used depending on data distribution and the multiple comparison tests.

For the statistical analysis software package, SPSS version 15.0, was used.

Statistical tests were considered significant at p ≤ 0.05.

Results

168 patients were included in the study, 130 women (77.38%) and 38 men (22.62%). Among the patients with RA, 8 (4.76%) were < 35 years, 60 (35.71%) were aged between 35 and 55 years, and 100 patients (59.52%) had > 55 years.

| Table 1. Distribution groups according to sex and age |
|---------------------------------|
| Patients | Age |
| Gender | Male | Female | < 35 | 35 – 55 | > 55 |
| No. | 38 | 130 | 8 | 60 | 100 |
| % | 22.62 | 77.38 | 4.76 | 35.71 | 59.52 |

The repartition of patients according to medication: 25 (14.88%) patients were treated with IFX, 18 (10.71%) with ADA, 34 (20.24%) with ETA and 91 (54.17%) with RTX.
The evolution of ESR, CRP and DAS 28 in patients treated with Infliximab

Patients selected for the study had initial values of ESR >15 mm/1h: 19 patients (76%) had ESR values between 15-35 mm/1h, and 6 patients (24%) had values >35 mm/1h.

At 6 months, the values for ESR were the following: 8 patients had ESR values <15mm/1h, 16 patients had values between 15-35mm/1h and 1 patient had ESR values of >35 mm/1h.

At 12 months, ESR values were the following: 24 patients <15 mm/1h and 1 patient was between 15-35mm/1h. No other patients had ESR values of >35 mm/1h.

The baseline levels of reactive C protein were the following: between 5-15 mg/ dl for 23 patients (92%) and for 2 patients (8%) 15> mg/ dl.

After 6 months of treatment, CRP values were <5 mg/ dl for 16 patients (64%), between 5-15 mg/ dl for 8 patients (32%), and only 1 patient (4%) had CRP of >15 mg/ dl.

After 12 months of treatment with Infliximab, the values for CRP were <5 mg/ dl for 24 patients (96%) and 1 patient (4%) had values between 5-15 mg/ dl. No other patients had CRP values of >15 mg/ dl.

The evolution of DAS 28 score under treatment with IFX is shown in Fig. 2.

The evolution of ESR, CRP and DAS 28 in patients treated with Adalimumab

Baseline value for Adalimumab group for ESR was between 15-35 mm/ 1h for 6 patients (33.33%) and >35 mm/ 1h for 12 patients (66.67%).

At 6 months, the values for ESR were <15 mm/ 1h for 4 patients (22.22%), between 15-35 mm/ 1h for 11 patients (61.11%) and >35 mm/ 1h for only 3 patients (16.67%).

The final analysis performed after 12 months of therapy with Adalimumab detected 16 patients (88.89%) with ESR values within the physiological limits (<15 mm/
11) and 2 patients (11.11%) with ESR between 15-35
mm/ 1h.

The baseline value for CRP was between 5-15
mg/ dl for 9 patients (50%) and >15 mg/ dl for 9 patients
(50%). No patients with CRP value of <5 mg/ dl were
included in the study.

At 6 months, the values for CRP were <5 mg/ dl
for 2 patients (11.11%), between 5-15 mg/ dl for 13
patients (72.22%) and >15 mg/ dl for only 3 patients
(16.67%).

At 12 months, the values for CRP were <5 mg/ dl
for 16 patients (88.89%), therefore in physiological limits
and between 5-15 mg/ dl for 2 patients (11.11%).

The evolution of DAS 28 score under treatment
with ADA is shown in Fig. 4.

The evolution of ESR, CRP and DAS 28 in patients
treated with Rituximab

Baseline value for ESR was between 15-35 mm/
1h for 62 patients (68.13%) and >35 mm/ 1h for 29
patients (31.87%).

Inflammatory samples taken at 6 months after
the initiation of therapy revealed 27 patients (29.67%) with
ESR <15 mm/ 1h, 59 patients (64.84%) with ESR values
between 15-35 mm/ 1h and 5 patients (5.49%) with ESR
> 35 mm/ 1h.

ESR analysis at 12 months after the initiation of
therapy revealed the following results: 70 patients
(69.22%) with ESR <15 mm/ 1h and 21 patients (23.08%)
with values between 15-35 mm/ 1h. No patient had values
of ESR> 35 mm/ 1h.

Baseline values of CRP were between 5-15 mg/
dl in 63 cases (69.23%) and >15 mg/ dl in 28 patients
(30.77%).

At 6 months after the beginning of treatment, the
samples showed values of CRP <5 mg/ dl in 26 cases
(28.57%), between 5-15 mg/ dl in 55 cases (60.44%), 10
patients with CRP of >15 mg/ dl (10.99%).

At 12 months it was found that 73 patients
(80.22%) had CRP values of <5 mg/ dl, 13 patients
(14.29%) had CRP in the range of 5-15 mg/ dl, 5 patients
(5.49%) had values of >15 mg/ dl.

The evolution of DAS 28 score under treatment
with RTX is shown in Fig. 5.

Comparing the values of the parameters
analyzed anytime between 0-6 months, 0-12 months or 6-
12 months, the patients have achieved significant
improvements over previous values assessments for
ESR, CRP and DAS 28.

At 6 months, the average ESR value was 16.68
± 6.19 for Infliximab, Etanercept 16.32 ± 6.98,
Adalimumab 21.89 ± 9.32 and 18.10 ± 7.72 for Rituximab
without noticing significant differences between therapies
(ANOVA 0.070).

Table 2. The evolution of ESR, CRP and DAS 28 for 12 months based on the average (Mean ± SD)

|                | Infliximab  | Etanercept | Adalimumab | Rituximab |
|----------------|-------------|------------|------------|-----------|
| Nr             | 25          | 34         | 18         | 91        |
| VSH_init       | 33.08 ± 18.12 | 32.59 ± 18.07 | 48.67 ± 22.96 | 33.80 ± 14.66 |
| VSH 6l         | 16.68±6.19  | 16.32±6.98 | 21.89±9.32 | 18.10±7.72 |
| VSH_12l        | 9.76±4.10   | 9.82±4.45  | 11.50±3.65 | 10.85±5.53 |
| CRP_init       | 11.44±10.89 | 10.25±5.64 | 23.36±23.94 | 17.00±16.00 |
| CRP 6l         | 5.92±1.16   | 4.85±0.48  | 10.33±1.10 | 8.63±0.83 |
| CRP_12l        | 2.62±2.72   | 2.19±1.53  | 3.34±1.68  | 4.66±1.42 |
| DAS28_init     | 5.72±0.32   | 5.72±0.40  | 5.69±0.44  | 5.60±0.30 |
| DAS28 6l       | 3.61±0.28   | 3.70±0.41  | 3.85±0.73  | 3.27±0.37 |
| DAS28_12l      | 2.35±0.33   | 1.97±0.53  | 2.35±0.73  | 2.08±0.61 |
Table 3. The evolution of ESR, CRP and DAS 28 for 12 months according to the median [25%; 75%]

|                | Infliximab | Etanercept | Adalimumab | Rituximab |
|----------------|------------|------------|------------|-----------|
| No VSH_init    | 28.00 [22.00, 34.00] | 27.00 [20.00, 35.00] | 39.00 [33.00, 68.25] | 29.00 [25.00, 38.00] |
| Median Values  | 27.00 [22.00, 34.00] | 27.00 [20.00, 35.00] | 39.00 [33.00, 68.25] | 29.00 [25.00, 38.00] |

Regarding CRP at 6 months, the values were 4.61 [3.58, 5.59] for the group under treatment with Infliximab, 4.48 [3.27, 5.3] for Etanercept, 6.825 [5.44, 10.53] for Adalimumab and 5.67 [4.68, 8.45] for Rituximab, with significant differences between therapies (p=0.000, Kruskal-Wallis) as it follows: Infliximab - Adalimumab (p = 0.003), Infliximab - Rituximab (p = 0.026), Etanercept - Adalimumab (p = 0.000), Etanercept - Rituximab (p = 0.000).

Median values for DAS 28 at 6 months were the following: 5.00 [4.82, 5.21] for the Infliximab group, 3.76 [3.16, 3.99] for Etanercept, 3.66 [3.17, 4.74] for Adalimumab group and 3.19 [3.01, 3.58] for Rituximab. There were significant differences between therapies (p=0.000, Kruskal-Wallis), as it follows: Infliximab - Rituximab (p = 0.000), Etanercept - Rituximab (p = 0.000), Adalimumab - Rituximab (p = 0.002).

Regarding ESR at 12 months, there were no significant differences between therapies (p=0.375, Kruskal-Wallis).

On the other hand, there were significant differences between therapies at 12 months regarding CRP (p=0.000, Kruskal-Wallis), as it follows: Infliximab - Rituximab (p = 0.010) and Etanercept - Rituximab (p = 0.000); values for each group: 1.93 [0.87, 3.05] for Etanercept, 3.39 [1.78, 4.38] for Adalimumab and 3.70 [2.12, 4.85] for patients treated with Rituximab.

For DAS 28 – the 12 months comparison revealed significant differences between groups (p=0.018, Kruskal-Wallis): Infliximab - Etanercept (p = 0.022); values for each group were 3.63 [3.41, 3.82] for Infliximab, and 1.83 [1.54, 2.43] in the group of patients treated with Etanercept.

**Conclusions**

All 4 therapies have proven efficient, prognostic markers decreasing progressively at 6 and 12 months.

Regarding ESR, there were no significant differences between groups at any time of the tests. Following the evolution of CRP, there were significant differences between the groups of patients at 6 months; the best response rate was seen in patients treated with Infliximab and Etanercept. The lowest response rate for CRP at 12 months was found in patients treated with Rituximab.

Regarding DAS 28, the clinical remission score, the best response was in the group of patients treated with Etanercept.

**Conflicts of interest:** None declared.

**Acknowledgments:** This work received financial support through the project entitled “CERO – Career profile: Romanian Researcher” grant number POSDRU/159/1.5/S/135760, co-financed by the European Social Fund for Sectoral Operational Programme Human Resources Development 2007-2013.

I would like also to thank physicians from “Dr. I. Canatuzu” Clinical Hospital, Bucharest, Clinic of Internal Medicine and Rheumatology, for providing patients.
References

1. Ionescu R. Esențialul în Reumatologie, 2006, Editura Amaltea, 214.
2. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JWJ, Boers M, Buttgerit F, Combe B, Cutole M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PLCM, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Islter T, Wong JB, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:508-516.
3. Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewe R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2013; Published Online First: 26 Sep 2013. doi:10.1136/annrheumdis-2013-204317.
4. Buch MH, Bingham SJ, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology. 2007; 46 (17):1153-1156.
5. Raffeiner B, Botsios C, Sfriso P, Ometto F, Bernardi L, Todesco S, Punzi L. Efficacy of low dose etanercept in maintaining clinical and radiological remission in rheumatoid arthritis. Ann Rheum Dis. 2010; 69: 102.
6. van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63:508-516.
7. Emery P, Fleischmann R, Filippowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hesse EW, Shaw TM. The efficacy and safety of Rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIIB randomized, double blind, placebo controlled, dose ranging trial. Arthritis Rheum. 2006; 54: 1390-1400.
8. Cohen SB, Emery P, Grieenwald MW, Dougados M et al. Rituximab for rheumatoid arthritis refractory to anti tumor necrosis factor therapy: results of a multicenter, randomized, double blind, placebo controlled, phase 3 trial, evaluating primary efficacy and safety at 24 weeks. Arthritis Rheum. 2006; 54: 2793-2806.
9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TWJ, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Paul P, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. 2010 Rheumatoid Arthritis Classification Criteria. An American College of Rheumatology/European League Against Rheumatism. Collaborative Initiative, Arthritis & Rheumatism, Vol. 62, No. 9, September 2010, 2569–2581.
11. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JWJ, Boers M, Buttgerit F, Combe B, Cutole M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PLCM, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Islter T, Wong JB, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204573.